Cargando…

Design and development of a biorelevant simulated human lung fluid

Biorelevant fluids are required to enable meaningful in vitro experimental determinations of the biopharmaceutical properties of inhaled medicines, e.g. drug solubility, particle dissolution, cellular uptake. Our aim was to develop a biorelevant simulated lung fluid (SLF) with a well-defined composi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassoun, Mireille, Royall, Paul G., Parry, Mark, Harvey, Richard D., Forbes, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156579/
https://www.ncbi.nlm.nih.gov/pubmed/30283501
http://dx.doi.org/10.1016/j.jddst.2018.08.006
_version_ 1783358133778776064
author Hassoun, Mireille
Royall, Paul G.
Parry, Mark
Harvey, Richard D.
Forbes, Ben
author_facet Hassoun, Mireille
Royall, Paul G.
Parry, Mark
Harvey, Richard D.
Forbes, Ben
author_sort Hassoun, Mireille
collection PubMed
description Biorelevant fluids are required to enable meaningful in vitro experimental determinations of the biopharmaceutical properties of inhaled medicines, e.g. drug solubility, particle dissolution, cellular uptake. Our aim was to develop a biorelevant simulated lung fluid (SLF) with a well-defined composition and evidence-based directions for use. The SLF contained dipalmitoylphosphotidylcholine, dipalmitoylphosphatidylglycerol, cholesterol, albumin, IgG, transferrin and antioxidants. Freshly made SLF had pH 7.2, viscosity 1.138 × 10(−3) Pa s, conductivity 14.5 mS/m, surface tension 54.9 mN/m and density 0.999 g/cm(3). Colour, surface tension and conductivity were the most sensitive indicators of product deterioration. The simulant was stable for 24 h and 48 h at 37 °C and 21 °C, respectively, (in-use stability) and for 14 days when stored in a refrigerator (storage stability). To extend stability, the SLF was vacuum freeze-dried in batches to produce lyophilised powder that can be reconstituted readily when needed at the point of use. In conclusion, we have reported the composition and manufacture of a biorelevant, synthetic SLF, provided a detailed physico-chemical characterisation and recommendations for how to store and use a product that can be used to generate experimental data to provide inputs to computational models that predict drug bioavailability in the lungs.
format Online
Article
Text
id pubmed-6156579
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61565792018-10-01 Design and development of a biorelevant simulated human lung fluid Hassoun, Mireille Royall, Paul G. Parry, Mark Harvey, Richard D. Forbes, Ben J Drug Deliv Sci Technol Article Biorelevant fluids are required to enable meaningful in vitro experimental determinations of the biopharmaceutical properties of inhaled medicines, e.g. drug solubility, particle dissolution, cellular uptake. Our aim was to develop a biorelevant simulated lung fluid (SLF) with a well-defined composition and evidence-based directions for use. The SLF contained dipalmitoylphosphotidylcholine, dipalmitoylphosphatidylglycerol, cholesterol, albumin, IgG, transferrin and antioxidants. Freshly made SLF had pH 7.2, viscosity 1.138 × 10(−3) Pa s, conductivity 14.5 mS/m, surface tension 54.9 mN/m and density 0.999 g/cm(3). Colour, surface tension and conductivity were the most sensitive indicators of product deterioration. The simulant was stable for 24 h and 48 h at 37 °C and 21 °C, respectively, (in-use stability) and for 14 days when stored in a refrigerator (storage stability). To extend stability, the SLF was vacuum freeze-dried in batches to produce lyophilised powder that can be reconstituted readily when needed at the point of use. In conclusion, we have reported the composition and manufacture of a biorelevant, synthetic SLF, provided a detailed physico-chemical characterisation and recommendations for how to store and use a product that can be used to generate experimental data to provide inputs to computational models that predict drug bioavailability in the lungs. Elsevier 2018-10 /pmc/articles/PMC6156579/ /pubmed/30283501 http://dx.doi.org/10.1016/j.jddst.2018.08.006 Text en © 2018 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hassoun, Mireille
Royall, Paul G.
Parry, Mark
Harvey, Richard D.
Forbes, Ben
Design and development of a biorelevant simulated human lung fluid
title Design and development of a biorelevant simulated human lung fluid
title_full Design and development of a biorelevant simulated human lung fluid
title_fullStr Design and development of a biorelevant simulated human lung fluid
title_full_unstemmed Design and development of a biorelevant simulated human lung fluid
title_short Design and development of a biorelevant simulated human lung fluid
title_sort design and development of a biorelevant simulated human lung fluid
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156579/
https://www.ncbi.nlm.nih.gov/pubmed/30283501
http://dx.doi.org/10.1016/j.jddst.2018.08.006
work_keys_str_mv AT hassounmireille designanddevelopmentofabiorelevantsimulatedhumanlungfluid
AT royallpaulg designanddevelopmentofabiorelevantsimulatedhumanlungfluid
AT parrymark designanddevelopmentofabiorelevantsimulatedhumanlungfluid
AT harveyrichardd designanddevelopmentofabiorelevantsimulatedhumanlungfluid
AT forbesben designanddevelopmentofabiorelevantsimulatedhumanlungfluid